ESR1 and breast carcinoma: A recent study by Kaplan et al indicated that ER+BRCA1-related breast cancers are indistinguishable from ER−BRCA1-related cancers in their nuclear expression of PARP-1, suggesting that ER+BRCA1-related breast cancers may respond well to drugs that exploit BRCA1 deficiency (15).